AR034692A1 - Inhibidores de la integrina alfavbeta3, un procedimiento para su preparacion, los medicamentos a base de estos compuestos, las composiciones farmaceuticas que los contienen y el uso de los mismos para preparar un medicamento destinado a combatir enfermedades que se basan en la expresion y funcion pa - Google Patents
Inhibidores de la integrina alfavbeta3, un procedimiento para su preparacion, los medicamentos a base de estos compuestos, las composiciones farmaceuticas que los contienen y el uso de los mismos para preparar un medicamento destinado a combatir enfermedades que se basan en la expresion y funcion paInfo
- Publication number
- AR034692A1 AR034692A1 ARP000104353A ARP000104353A AR034692A1 AR 034692 A1 AR034692 A1 AR 034692A1 AR P000104353 A ARP000104353 A AR P000104353A AR P000104353 A ARP000104353 A AR P000104353A AR 034692 A1 AR034692 A1 AR 034692A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- compounds
- unsubstituted
- inhibitors
- ocf3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Se describen inhibidores de la integrina alfavbeta3 de fórmula (1): X-Y-Z-R1-CH2-R2(R4)-CH2-CO-R5, en donde: X significa H2N-C(=NH)-, H2N-C(=NH)-NH, A-C(=NH)-NH-, Het1- ó Het1-NH-, donde los grupos amino primarios también pueden estar provistos con grupos protectores de amino convencionales; Y significa -(CH2)n, ó un compuesto de fórmula (2) donde 1, 2, 3 ó 4 grupo metileno pueden estar reemplazados por N, O y/o S; Z está ausente o significa -O-, -NH-, -NA-, -CH(OH)-, -CH(OA)-, -CHA-, -CA2- ó -S-; R1 significa fenileno no sustituido o sustituido 1, 2 ó 3 veces con F, Cl, Br, A, OA, OCF3 ó CN; R2 significa N, CH ó CA; R3 significa H, F, Cl, Br, A, OA ó OCF3; R4 significa fenilo, naftilo o Het2 no sustituido o sustituido una o varias veces con A, arilo ó CF3; R5 significa OH, OA, NH2, NHA ó NA2; Het1 significa un heterociclo de 1 ó 2 núcleos con 1 a 4 átomos de N, que puede estar no sustituido o sustituido 1-2 veces con NH2; Het2 significa un heterociclo aromático de 1 ó 2 núcleos con 1 a 3 átomos de N, O y/o S, que puede estar no sustituido o sustituido 1 ó 2 veces con F, Cl, Br, A, OA, SA, OCF3, -CO-A, CN, COOA, CONH2, CONHA, CONA2 ó NO2; Arilo significa fenilo no sustituido o sustituido 1, 2 ó 3 veces con Hal, A u OA; A significa alquilo C1-12; n significa de 1 a 12; m y o independientemente entre sí significan de 1 a 12; así como sus sales y solvatos fisiológicamente inofensivos. Estos compuestos inhiben especialmente las interacciones de los receptores alfav con los ligando, siendo especialmente efectivos como ligandos de la integrina alfavbeta3. También se describe un procedimiento para preparar los compuestos de fórmula (1), los medicamentos a base de estos compuestos, las composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de un medicamento para combatir las enfermedades que se basan en la expresión y la función patológica de receptores de integrina alfavbeta3, en particular, para combatir la trombosis, el infarto de miocardio, las enfermedades cardíacas coronarias, la arteriosclerosis, los tumores, la osteoporosis, la fibrosis, las inflamaciones, las infecciones, lapsoriasis, así como para influir sobre los procesos de curación de heridas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19939980A DE19939980A1 (de) | 1999-08-24 | 1999-08-24 | Inhibitoren des Integrins alphavbeta¶3¶ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034692A1 true AR034692A1 (es) | 2004-03-17 |
Family
ID=7919342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104353A AR034692A1 (es) | 1999-08-24 | 2000-08-23 | Inhibidores de la integrina alfavbeta3, un procedimiento para su preparacion, los medicamentos a base de estos compuestos, las composiciones farmaceuticas que los contienen y el uso de los mismos para preparar un medicamento destinado a combatir enfermedades que se basan en la expresion y funcion pa |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6645991B1 (es) |
| EP (1) | EP1206455A1 (es) |
| JP (1) | JP2003507457A (es) |
| KR (1) | KR20020086849A (es) |
| CN (1) | CN1370146A (es) |
| AR (1) | AR034692A1 (es) |
| AU (1) | AU6992500A (es) |
| BR (1) | BR0013502A (es) |
| CA (1) | CA2382561A1 (es) |
| CZ (1) | CZ2002525A3 (es) |
| DE (1) | DE19939980A1 (es) |
| HK (1) | HK1049667A1 (es) |
| HU (1) | HUP0203212A3 (es) |
| MX (1) | MXPA02001862A (es) |
| NO (1) | NO20020885L (es) |
| PL (1) | PL352987A1 (es) |
| SK (1) | SK2272002A3 (es) |
| WO (1) | WO2001014337A1 (es) |
| ZA (1) | ZA200202284B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008696D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic agents |
| US6900232B2 (en) | 2000-06-15 | 2005-05-31 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| DE10063173A1 (de) * | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
| AU783516B2 (en) | 2001-04-30 | 2005-11-03 | Warner-Lambert Company | Methods, kits and compositions for using pyrrole derivatives |
| WO2003034995A2 (en) * | 2001-10-22 | 2003-05-01 | The Scripps Research Institute | Integrin targeting compounds |
| MXPA05013637A (es) * | 2003-08-13 | 2006-02-24 | Chiron Corp | Inhibidores gsk-3 y usos de los mismos. |
| WO2005117954A2 (en) | 2004-06-04 | 2005-12-15 | The Scripps Research Institute | Compositions and methods for treatment of neovascular diseases |
| WO2006111925A2 (en) * | 2005-04-18 | 2006-10-26 | Sloan-Kettering Institute For Cancer Research | Inhibition of tumorigenesis by inhibition of a6b4 integrin |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234936A (en) * | 1991-10-24 | 1993-08-10 | American Home Products Corporation | Pyrimidocycloalkanes as a ii antagonists |
| US5654322A (en) * | 1992-08-11 | 1997-08-05 | Wakunaga Seiyaku Kabushiki Kaisha | Biphenylmethane derivatives and pharmaceuticals containing the same |
| EP0628559B1 (en) * | 1993-06-10 | 2002-04-03 | Beiersdorf-Lilly GmbH | Pyrimidine compounds and their use as pharmaceuticals |
| CN1209063A (zh) | 1995-12-29 | 1999-02-24 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
| JP2000506538A (ja) * | 1996-03-29 | 2000-05-30 | ジー．ディー．サール アンド カンパニー | メタ―置換フェニレン誘導体 |
| WO1997036882A1 (en) | 1996-04-03 | 1997-10-09 | Takeda Chemical Industries, Ltd. | Oxazole derivatives, their production and use |
| EA200000921A1 (ru) | 1998-03-10 | 2001-04-23 | Смитклайн Бичам Корпорейшн | Антагонисты рецептора витронектина |
| IL145401A0 (en) | 1999-03-24 | 2002-06-30 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
-
1999
- 1999-08-24 DE DE19939980A patent/DE19939980A1/de not_active Withdrawn
-
2000
- 2000-08-04 MX MXPA02001862A patent/MXPA02001862A/es unknown
- 2000-08-04 HU HU0203212A patent/HUP0203212A3/hu unknown
- 2000-08-04 JP JP2001518426A patent/JP2003507457A/ja active Pending
- 2000-08-04 PL PL00352987A patent/PL352987A1/xx unknown
- 2000-08-04 BR BR0013502-0A patent/BR0013502A/pt not_active IP Right Cessation
- 2000-08-04 CZ CZ2002525A patent/CZ2002525A3/cs unknown
- 2000-08-04 US US10/069,187 patent/US6645991B1/en not_active Expired - Fee Related
- 2000-08-04 EP EP00958381A patent/EP1206455A1/de not_active Withdrawn
- 2000-08-04 KR KR1020027001418A patent/KR20020086849A/ko not_active Application Discontinuation
- 2000-08-04 SK SK227-2002A patent/SK2272002A3/sk unknown
- 2000-08-04 CN CN00811880A patent/CN1370146A/zh active Pending
- 2000-08-04 AU AU69925/00A patent/AU6992500A/en not_active Abandoned
- 2000-08-04 WO PCT/EP2000/007590 patent/WO2001014337A1/de not_active Application Discontinuation
- 2000-08-04 CA CA002382561A patent/CA2382561A1/en not_active Abandoned
- 2000-08-23 AR ARP000104353A patent/AR034692A1/es not_active Application Discontinuation
-
2002
- 2002-02-22 NO NO20020885A patent/NO20020885L/no not_active Application Discontinuation
- 2002-03-20 ZA ZA200202284A patent/ZA200202284B/en unknown
-
2003
- 2003-03-13 HK HK03101817.6A patent/HK1049667A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200202284B (en) | 2003-08-27 |
| WO2001014337A1 (de) | 2001-03-01 |
| HK1049667A1 (zh) | 2003-05-23 |
| EP1206455A1 (de) | 2002-05-22 |
| AU6992500A (en) | 2001-03-19 |
| HUP0203212A2 (hu) | 2003-02-28 |
| NO20020885D0 (no) | 2002-02-22 |
| CA2382561A1 (en) | 2001-03-01 |
| CZ2002525A3 (cs) | 2002-05-15 |
| SK2272002A3 (en) | 2002-06-04 |
| DE19939980A1 (de) | 2001-03-01 |
| KR20020086849A (ko) | 2002-11-20 |
| PL352987A1 (en) | 2003-09-22 |
| US6645991B1 (en) | 2003-11-11 |
| MXPA02001862A (es) | 2002-10-23 |
| CN1370146A (zh) | 2002-09-18 |
| NO20020885L (no) | 2002-02-22 |
| JP2003507457A (ja) | 2003-02-25 |
| HUP0203212A3 (en) | 2005-02-28 |
| BR0013502A (pt) | 2002-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| BR9908764A (pt) | Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| UY25811A1 (es) | Derivados de pirrolidina que son antagonistas del receptor ccr-3 | |
| UY26968A1 (es) | Agentes terapéuticos | |
| ES2196377T3 (es) | Derivados de naftiridina. | |
| HUP0301607A2 (hu) | Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| AR029766A1 (es) | Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica | |
| MX9305379A (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene. | |
| AR027437A1 (es) | Derivados de purina | |
| AR029383A1 (es) | Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes | |
| BR0010476A (pt) | Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais | |
| HUP0401307A2 (hu) | 5-HT6 hatással rendelkező új indolszármazékok, eljárás az előállításukra, és ezeket tartalmazó gyógyszerkészítmények | |
| BRPI0316264B8 (pt) | compostos, seu uso e formulação farmacêutica que os contém | |
| AR004291A1 (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
| AR032781A1 (es) | Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen | |
| AR054508A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| AR034692A1 (es) | Inhibidores de la integrina alfavbeta3, un procedimiento para su preparacion, los medicamentos a base de estos compuestos, las composiciones farmaceuticas que los contienen y el uso de los mismos para preparar un medicamento destinado a combatir enfermedades que se basan en la expresion y funcion pa | |
| ES2038172T3 (es) | Procedimiento para preparar carboxamidas heterociclicas. | |
| AR034204A1 (es) | Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares | |
| RU2010116779A (ru) | Производное амида индазолакриловой кислоты | |
| AR007060A1 (es) | Inhibidores de la formacion de la cd23 humana soluble, el uso de los mismos una composicion farmaceutica que los comprende, un metodo para preparar dichosinhibidores y compuestos intermediarios | |
| AR010899A1 (es) | Oxazolidinonas, un procedimiento para su preparacion, el empleo de las mismas para preparar un medicamento, medicamentos y preparaciones farmaceuticasque las contienen y un procedimiento para obtener estas preparaciones farmaceuticas. | |
| BG106847A (en) | Substituted piperazine derivatives as mtp inhibitors | |
| ES2172294T3 (es) | Nuevos derivados del 1-indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |